The estimated Net Worth of Philina Lee is at least $2.72 Milion dollars as of 5 August 2024. Philina Lee owns over 41,913 units of Fusion Pharmaceuticals stock worth over $1,651,635 and over the last 4 years Philina sold FUSN stock worth over $1,067,923.
Sign up
Philina Lee FUSN stock SEC Form 4 insiders trading
Philina has made over 5 trades of the Fusion Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently Philina exercised 41,913 units of FUSN stock worth $2,829,128 on 5 August 2024.
The largest trade Philina's ever made was exercising 41,913 units of Fusion Pharmaceuticals stock on 5 August 2024 worth over $2,829,128. On average, Philina trades about 4,567 units every 43 days since 2021. As of 5 August 2024 Philina still owns at least 76,642 units of Fusion Pharmaceuticals stock.
You can see the complete history of Philina Lee stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Philina Lee's mailing address?
Philina's mailing address filed with the SEC is C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Insiders trading at Fusion Pharmaceuticals
Over the last 4 years, insiders at Fusion Pharmaceuticals have traded over $1,703,181 worth of Fusion Pharmaceuticals stock and bought 2,415,900 units worth $40,298,362 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Street Partners Llc Adams oraz & Johnson Johnson & Johnson.... On average, Fusion Pharmaceuticals executives and independent directors trade stock every 28 days with the average trade being worth of $2,030,355. The most recent stock trade was executed by Steven Gannon on 11 August 2022, trading 44,400 units of FUSN stock currently worth $90,132.
What does Fusion Pharmaceuticals do?
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
What does Fusion Pharmaceuticals's logo look like?
Complete history of Philina Lee stock trades at Blueprint Medicines Corp i Fusion Pharmaceuticals
Fusion Pharmaceuticals executives and stock owners
Fusion Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Dr. John F. Valliant,
Founder, CEO & Director -
John J. Crowley CPA,
Chief Financial Officer -
Dr. Eric Burak Ph.D.,
Chief Technology Officer -
Dr. James J. O'Leary,
Chief Medical Officer -
Dr. Eric Burak,
Chief Scientific Officer -
Eric S. Hoffman Ph.D.,
Sr. VP of Bus. Devel. -
Dr. Isabelle Dussault Ph.D.,
Sr. VP of Research -
Dr. Christopher Paul Leamon Ph.D.,
Chief Scientific Officer -
Mohit Rawat,
Pres & Chief Bus. Officer -
Dr. Marc Schwabish,
SVP of Bus. Devel. and US Operations -
Maria D. Stahl,
Chief Legal Officer -
Amanda Cray,
Sr. Director of Investor Relations & Corp. Communications -
Lynn Wick,
Exec. Director of Fin. & Operations -
Group Holdings (Sbs) Adviso...,
-
Johan Christenson,
Director -
Vii, L.P.Health Cap Vii Gp ...,
-
Heather Preston,
Director -
Street Partners Llc Adams,
10% owner -
James J O'leary,
Chief Medical Officer -
Chau Quang Khuong,
Director -
Advisors Llc Orbi Med Capit...,
-
& Johnson Johnson & Johnson...,
-
Steven Gannon,
-
Teresa Marie Bitetti,
-
Jeremy Bender,
-
Pablo J Cagnoni,
-
Donald A Bergstrom,
-
Christopher P Leamon,
Chief Scientific Officer -
Mohit Rawat,
President & CBO -
David D. Meek,
-
Dmitri Bobilev,
Chief Medical Officer -
Eric Burak,
Chief Technology Officer -
John J Crowley,
Chief Financial Officer -
John Valliant,
Chief Executive Officer -
Philina Lee,
-
Barbara Gayle Duncan,